Free Trial
NASDAQ:HOOK

Hookipa Pharma (HOOK) Stock Price, News & Analysis

Hookipa Pharma logo
$0.82 -0.03 (-3.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.82 0.00 (-0.12%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Hookipa Pharma Stock (NASDAQ:HOOK)

Key Stats

Today's Range
$0.82
$0.90
50-Day Range
$0.85
$2.17
52-Week Range
$0.82
$10.50
Volume
32,139 shs
Average Volume
116,937 shs
Market Capitalization
$9.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00
Consensus Rating
Hold

Company Overview

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Remove Ads

Hookipa Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

HOOK MarketRank™: 

Hookipa Pharma scored higher than 32% of companies evaluated by MarketBeat, and ranked 730th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hookipa Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Hookipa Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Hookipa Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Hookipa Pharma are expected to decrease in the coming year, from ($1.75) to ($2.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hookipa Pharma is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hookipa Pharma is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Hookipa Pharma has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Hookipa Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    1.03% of the float of Hookipa Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Hookipa Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hookipa Pharma has recently increased by 6.65%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Hookipa Pharma does not currently pay a dividend.

  • Dividend Growth

    Hookipa Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.03% of the float of Hookipa Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Hookipa Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hookipa Pharma has recently increased by 6.65%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    3 people have searched for HOOK on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Hookipa Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hookipa Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.30% of the stock of Hookipa Pharma is held by insiders.

  • Percentage Held by Institutions

    63.88% of the stock of Hookipa Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hookipa Pharma's insider trading history.
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

HOOK Stock News Headlines

Hookipa Pharma (HOOK) Expected to Announce Earnings on Friday
Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Trump Treasure April 19
Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Headlines

HOOK Stock Analysis - Frequently Asked Questions

Hookipa Pharma's stock was trading at $2.01 at the beginning of 2025. Since then, HOOK stock has decreased by 59.0% and is now trading at $0.8250.
View the best growth stocks for 2025 here
.

Hookipa Pharma Inc (NASDAQ:HOOK) released its earnings results on Thursday, August, 8th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.08. The firm had revenue of $1.29 million for the quarter, compared to analysts' expectations of $5.68 million. Hookipa Pharma had a negative net margin of 86.74% and a negative trailing twelve-month return on equity of 33.31%.

Hookipa Pharma's stock reverse split before market open on Wednesday, July 10th 2024. The 1-10 reverse split was announced on Wednesday, July 10th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Hookipa Pharma (HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hookipa Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Pfizer (PFE), Advanced Micro Devices (AMD), Cabaletta Bio (CABA) and Novo Nordisk A/S (NVO).

Company Calendar

Last Earnings
8/08/2024
Today
4/04/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.00
High Stock Price Target
$60.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+2,687.9%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-81,580,000.00
Pretax Margin
-86.42%

Debt

Sales & Book Value

Annual Sales
$43.95 million
Price / Cash Flow
N/A
Book Value
$9.08 per share
Price / Book
0.09

Miscellaneous

Free Float
11,657,000
Market Cap
$9.95 million
Optionable
Optionable
Beta
0.78
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:HOOK) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners